Ninlib 200 mg Ninlib 200 mg contains Nilotinib 200 mg, a targeted anti-cancer medicine mainly used to treat certain forms of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It works by blocking the abnormal BCR-ABL protein that continuously signals leukemia cells to grow and multiply. By suppressing this abnormal signaling, Ninlib helps reduce the production of abnormal blood cells and supports long-term control of the disease. It is taken orally according to the treatment plan prescribed by the oncologist.